AU2019321089A1 — Liquid bendamustine pharmaceutical compositions
Assigned to Hospira Australia Pty Ltd · Expires 2021-02-11 · 5y expired
What this patent protects
Concentrated liquid pharmaceutical compositions comprising a) a pharmaceutically effective amount of bendamustine or a pharmaceutically acceptable salt thereof, b) a non-aqueous solvent, and c) at least about 2% water, suitable, after dilution, for administration to a mammal by i…
USPTO Abstract
Concentrated liquid pharmaceutical compositions comprising a) a pharmaceutically effective amount of bendamustine or a pharmaceutically acceptable salt thereof, b) a non-aqueous solvent, and c) at least about 2% water, suitable, after dilution, for administration to a mammal by injection are provided. The concentrated liquid pharmaceutical compositions can comprise a non-aqueous solvent comprising at least one organic polymeric compound solvent and at least one organic small molecule solvent. Methods of treating a cancer in a mammal in need of such treatment comprising administering to the mammal an effective amount of a concentrated liquid bendamustine pharmaceutical composition of the invention are also provided.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.